URL has been copied successfully!
This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
Kyle Diamantas, the acting commissioner of the Food and Drug Administration — newly installed following Marty Makary’s resignation — is expected to be a drama-free, stabilizing caretaker at the top of the agency.
Leadership turnover is always going to cause some angst, but based on what I’m hearing, biotech and the investors who track the sector have little to fear from Diamantas. He is stepping into the new role after serving as the FDA’s top food regulator.
Please follow us:
